Nalaganje...
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of treatments for type 2 diabetes that offer multifactorial benefits, including glycemic control, weight loss and low hypoglycemia risk. Once-weekly semaglutide is a novel GLP-1 analog that has been associated with imp...
Shranjeno v:
| izdano v: | Adv Ther |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Healthcare
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6822857/ https://ncbi.nlm.nih.gov/pubmed/31168765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00965-y |
| Oznake: |
Označite
Brez oznak, prvi označite!
|